Yüklüyor......
Bosutinib in chronic myeloid leukemia: patient selection and perspectives
During recent years, the therapeutic landscape in chronic myeloid leukemia (CML) has changed significantly. Since the clinical introduction of tyrosine kinase inhibitors (TKIs) approximately 15 years ago, patients’ concerns have shifted from reduced life expectancy toward long-term toxicities of TKI...
Kaydedildi:
| Yayımlandı: | J Blood Med |
|---|---|
| Asıl Yazarlar: | , |
| Materyal Türü: | Artigo |
| Dil: | Inglês |
| Baskı/Yayın Bilgisi: |
Dove Medical Press
2018
|
| Konular: | |
| Online Erişim: | https://ncbi.nlm.nih.gov/pmc/articles/PMC5905837/ https://ncbi.nlm.nih.gov/pubmed/29695943 https://ncbi.nlm.nih.govhttp://dx.doi.org/10.2147/JBM.S129821 |
| Etiketler: |
Etiketle
Etiket eklenmemiş, İlk siz ekleyin!
|